First Successful In Vivo Gene Editing for the Treatment of Hereditary Angioedema
In trials, the CRISPR therapy NTLA-2002 reduced attack frequency by 95% with a single dose, paving the way for a cure for severe hereditary angioedema.
Introduction
In April 2026, Intellia Therapeutics announced results that could forever change the approach to treating hereditary diseases. The global Phase III HAELO study demonstrated that a single infusion of lonvoguran ziclumeran (lonvo-z, formerly known as NTLA-2002) reduced the frequency of hereditary angioedema (HAE) attacks by 87% compared to placebo, and 62% of patients were completely free of attacks and no longer needed ongoing therapy.
Hereditary angioedema is a rare genetic disorder in which patients experience recurrent, severe, and potentially fatal swelling of the face, upper airways, abdomen, and limbs. It is caused by excessive bradykinin production due to mutations in the SERPING1 gene, leading to uncontrolled plasma kallikrein activity. Until now, patients had to take lifelong prophylactic medications—daily pills or injections every 2–4 weeks—which did not always prevent breakthrough attacks.
Lonvoguran is based on the CRISPR/Cas9 genome editing system and is administered as a single intravenous infusion. Its mechanism of action is fundamentally different: it does not temporarily suppress symptoms but instead intervenes in the patient's DNA to permanently disable the cause of the disease.
Event Details and Timeline
Early Stages: Phase I (2021–2023). The first safety and efficacy data for NTLA-2002 emerged in 2023. In an interim analysis of Phase I, 10 patients experienced an average 95% reduction in monthly attack rate after a single dose. The median follow-up was 9 months, and all adverse effects were mild.
Phase II Publication in NEJM (January 2025). A randomized Phase II study involving 27 patients showed impressive results. From weeks 1 to 16, the mean attack rate was 0.70 per month at the 25 mg dose and 0.65 at the 50 mg dose, compared to 2.82 in the placebo group—a reduction of 75–77%. 73% of patients receiving 50 mg were completely free of attacks without additional treatment. Kallikrein levels decreased by 86% at the 50 mg dose. Later data showed an 81% reduction in attacks when analyzing weeks 5–16, and at the 50 mg dose, 73% of patients remained attack-free at a median follow-up of 8 months.
Key Milestone: Phase III Launch (January 2025). The first patient was enrolled in the global HAELO study on January 22, 2025. This double-blind, placebo-controlled study with 80 patients (ultimately exceeding the planned 60) randomized them 2:1 to receive a single infusion of 50 mg of the drug or placebo.
Breakthrough: Phase III Results (April 2026). On April 26, 2026, Intellia announced the long-awaited top-line results. The study met its primary endpoint: over the 6-month evaluation period (weeks 5–28), the drug reduced attacks by 87% compared to placebo. The mean attack rate was 0.26 in the lonvo-z group versus 2.10 in the placebo group. All key secondary endpoints were also met with high statistical significance (p<0.0001). Most importantly, 62% of patients receiving lonvo-z were completely free of attacks and required no therapy throughout the observation period, compared to 11% in the placebo group.
Safety Profile. As of the data cutoff (February 10, 2026), the most common adverse events were infusion reactions, headache, and fatigue. All side effects were mild or moderate, with no serious adverse events reported in the lonvo-z group. All patients who received the drug remained free from the need for ongoing prophylactic therapy.
Regulatory Pathway. Thanks to the Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, Intellia initiated a rolling Biologics License Application (BLA) submission in April 2026. The company plans to complete the submission in the second half of 2026 and, if approved, launch the drug in the US market in the first half of 2027.
Impact and Significance
For the Scientific World. The Phase III HAELO results represent the first successful completed Phase 3 for an in vivo CRISPR-based therapy. As Intellia CEO John Leonard stated, "These results are a profound milestone for Intellia, for the entire field of CRISPR and precision medicine, and most importantly, for the hereditary angioedema patient community."
Until now, in vivo gene editing remained largely a theoretical possibility, confirmed only by early-phase studies. The success of lonvo-z proves that systemic administration of CRISPR/Cas9 therapy is safe, effective, and capable of providing long-lasting—potentially lifelong—effects.
For the Pharmaceutical Industry. Approval of lonvo-z could catalyze an entire wave of in vivo therapies in development. Intellia has already announced plans to bring the drug to market in 2027. Notably, the drug is administered as a single outpatient infusion, radically different from existing HAE treatments—daily Orladeyo (BioCryst) or injections of Takhzyro (Takeda) every 2–4 weeks.
For Patients. Living with HAE means constant anxiety about the next attack, which can be fatal if it involves laryngeal edema. For patients who have struggled for years with unpredictable breakthrough attacks, anxiety, and the burden of ongoing therapy, lonvo-z represents a "potential paradigm shift in treatment." The possibility of achieving a functional cure with a single infusion is not just medical progress; it is regaining control over one's own life.
Key Stakeholder Reactions
Intellia Therapeutics. The company is naturally at the center of events. Beyond announcing Phase III results, it has already initiated a rolling BLA submission to the FDA and is preparing for a commercial launch in the first half of 2027. John Leonard emphasized that the drug "could free most patients from both attacks and the need for ongoing therapy."
Scientific Community and Physicians. The Phase II results were published in the New England Journal of Medicine (January 2025), underscoring the scientific significance of the discovery. Dr. Joshua Jacobs, Medical Director of Allergy and Asthma Clinical Research, called the therapy "a new generation of treatment that could potentially provide patients with lifelong relief from the core symptoms of HAE."
Competitors. The HAE prophylaxis market is dominated by BioCryst (Orladeyo) and Takeda (Takhzyro). Both drugs are effective but require lifelong adherence. If lonvo-z is approved, it will create a fundamentally new category—a functional cure with a single dose. This could radically reshape the market.
Regulators. The FDA granted lonvo-z RMAT and Orphan Drug designations, and included Intellia in a pilot program for CMC development, accelerating interactions. All this indicates a high level of regulatory confidence in the technology and data.
Forecast and Conclusions
Lonvoguran ziclumeran is the first in vivo CRISPR-based therapy to successfully complete Phase III. This is not just new hope for patients with hereditary angioedema. It is confirmation that gene editing inside the patient's body is safe, effective, and scalable. The technology has left the laboratory and moved closer to everyday clinical practice.
Key facts shaping the future:
- Data are compelling. 87% reduction in attack rate, no serious adverse events, and sustained effect throughout the observation period.
- Path to market is clear. BLA submission has begun, completion expected in the second half of 2026, potential launch in the first half of 2027.
- Technology is proven. The success of lonvo-z paves the way for other in vivo therapies from Intellia, including NTLA-2001 for transthyretin amyloidosis.
Of course, questions remain that only time will answer: How long does the effect last after a single dose? Is an immune response to CRISPR components possible years later? Will patients and physicians abandon familiar treatment regimens in favor of a radical but unknown alternative?
Nevertheless, April 2026 will go down in history as the moment when in vivo CRISPR therapy ceased to be a promise and became a reality. For thousands of people living with the threat of sudden, painful, and sometimes fatal swelling, this means their disease will no longer dictate the terms of their lives. A single infusion—and a new chapter can begin.
— Editorial Team
